FCMI
EPZM

Foresite Capital Management III’s Epizyme, Inc EPZM Stock Holding History

Foresite Capital Management III’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-998,278
Closed -$5.11M – 7
2021
Q3 		$5.11M Hold
998,278
– – 7.09% 5
2021
Q2 		$8.3M Hold
998,278
– – 8.79% 4
2021
Q1 		$8.7M Hold
998,278
– – 7.64% 6
2020
Q4 		$10.8M Hold
998,278
– – 12.6% 5
2020
Q3 		$11.9M Hold
998,278
– – 8.87% 5
2020
Q2 		$16M Buy
998,278
+284,466
+40% +$4.97M 14.26% 4
2020
Q1 		$11.1M Buy
713,812
+26,385
+4% +$567K 17.63% 2
2019
Q4 		$16.9M Sell
687,427
-310,851
-31% -$4.61M 9.48% 4
2019
Q3 		$10.3M Hold
998,278
– – 3.93% 8
2019
Q2 		$12.5M Hold
998,278
– – 4.11% 8
2019
Q1 		$12.4M Buy
998,278
+63
+0% +$704 3.22% 10
2018
Q4 		$6.15M Buy
998,215
+80,500
+9% +$615K 2.02% 13
2018
Q3 		$9.73M Sell
917,715
-22,970
-2% -$262K 2.15% 14
2018
Q2 		$12.7M Sell
940,685
-57,593
-6% -$896K 2.74% 11
2018
Q1 		$17.7M Hold
998,278
– – 3.86% 11
2017
Q4 		$12.5M Buy
998,278
+148,585
+17% +$2.16M 3.52% 9
2017
Q3 		$16.2M Buy
849,693
+50,330
+6% +$768K 4.46% 8
2017
Q2 		$12.1M Buy
799,363
+117,441
+17% +$1.78M 3.94% 8
2017
Q1 		$11.7M Buy
681,922
+76,683
+13% +$1.02M 4.49% 6
2016
Q4 		$7.32M Sell
605,239
-6,538
-1% -$68.2K 3.18% 10
2016
Q3 		$6.02M Buy
611,777
+100,000
+20% +$913K 2.81% 10
2016
Q2 		$5.24M Buy
511,777
+35,000
+7% +$390K 3.6% 7
2016
Q1 		$5.78M Buy
476,777
+15,126
+3% +$153K 4.47% 6
2015
Q4 		$7.4M Buy
+461,651
New +$6.84M 6.56% 4

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Foresite Capital Management III's EPZM Position: Q4 2021 in Review

Foresite Capital Management III sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 998,278 shares — an estimated $5.11M sold.

Foresite Capital Management III first reported a position in EPZM in Q4 2015 and held it in 24 quarters. The position peaked at $17.7M in Q1 2018. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Foresite Capital Management III reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Foresite Capital Management III sold 998,278 Epizyme, Inc shares in Q4 2021, an estimated $5.11M.
  • Foresite Capital Management III first reported a position in Epizyme, Inc in Q4 2015 and held it in 24 quarters.
  • Foresite Capital Management III's Epizyme, Inc position peaked at $17.7M in Q1 2018.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Foresite Capital Management III's 13F filing for Q4 2021, filed 11 Feb 2022.